- CLINICAL BRIEFINGS
- 07 September 2022
For breast cancers that have spread, a randomized phase II clinical trial shows that using genomic analysis to target therapies can improve outcomes, but only in people with a genetic alteration that has previously been associated with antitumour activity in clinical trials.
More News
Author Correction: Bitter taste receptor activation by cholesterol and an intracellular tastant – Nature
Audio long read: How does ChatGPT ‘think’? Psychology and neuroscience crack open AI large language models
Ozempic keeps wowing: trial data show benefits for kidney disease